Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459409 | 1.00 | GBA1 (0.43) | GBA1SLC18A3CYP2C9CYP2C19HTR2B | |
| SCHEMBL23459251 | 1.00 | GBA1 (0.43) | GBA1SLC18A3CYP2C9CYP2C19HTR2B | |
| SCHEMBL6326488 | 1.00 | GBA1 (0.43) | GBA1SLC18A3CYP2C9CYP2C19HTR2B | |
| SCHEMBL23459412 | 1.00 | GBA1 (0.43) | GBA1SLC18A3CYP2C9CYP2C19HTR2B | |
| SCHEMBL23459106 | 0.91 | SLC18A3 (0.48) | SLC18A3CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL23459107 | 0.91 | SLC18A3 (0.48) | SLC18A3CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL21461278 | 0.88 | TACR1 (0.40) | GBA1SLC18A3CYP2C9CYP2C19HTR2B | |
| SCHEMBL1313049 | 0.86 | GBA1 (0.45) | GBA1CYP2C9MEN1KMT2A | |
| SCHEMBL17542008 | 0.83 | ABCB1 (0.43) | GBA1SLC18A3CYP2C9CYP2C19HTR2B | |
| SCHEMBL28879326 | 0.83 | ABCB1 (0.43) | GBA1SLC18A3CYP2C9CYP2C19HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | GBA1 2424/4885SLC18A3 1405/4885CYP2C9 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.